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Abstract
The purpose of this study was to investigate the effect of soybean on blood glucose and lipid concentrations, and antioxidant enzyme activity
in type 2 diabetes mellitus (DM) patients. We divided patients into two groups and fed them, respectively, a basal diet (control group) and a basal
diet with 69 g/d of soybean (soybean group) for 4 weeks. Pills with roasted soybean powder were provided to the soybean supplementation group
three times a day. Macronutrients intake except dietary fiber was similar between the two groups. No significant differences were observed in dietary
intakes or body weight before and after the supplementation. Energy composition ratio of C:F:P was 65:19:16 in the control group, 64:20:16 in
the soybean group. The blood parameters of subjects before supplementation, such as fasting blood glucose, postprandial glucose level, total cholesterol,
triglyceride, LDL-cholesterol and HbA1C were not different between the two groups. After supplementation, fasting blood glucose (p<0.001), postprandial
glucose level (p<0.001) and serum triglyceride level (p<0.05) were significantly reduced in the soybean group in comparison with the control group.
The total cholesterol level was not significantly different between the control and the supplemented group after 4 weeks of treatment. TBARS levels
of the soybean group were not significantly different from those of the control group. The activities of catalase (p<0.01) and glutathione peroxidase
(p<0.05) were significantly higher in the soybean group compared to the control group. The results of this study suggest that soybean supplementation 
would be helpful to control blood glucose and serum lipid in diabetic patients. Also, soybean showed an antioxidant activity that may contribute
to enhance the effect of antioxidant defense. This activity contributes to protection against oxidative damage in type 2 DM patients. Soybean may
have potential use in the disease management of patients with DM.
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Introduction2)
The prevalence of diabetes mellitus (DM) is increasing 
worldwide, and it will be a major health problem in the 21st 
century. Worldwide prevalence of DM was estimated to be 177 
million cases in 2000 and is projected to increase to 366 million 
by 2030, largely owing to an aging population, increased urbani-
zation, and more sedentary lifestyles (Wild et al., 2004). 
The metabolic characteristics of diabetes patients are 
abnormally high concentrations of glucose in the blood and lipid 
metabolic abnormality (Coulston & Hollenbeck, 1988). The 
serum lipid abnormalities in type 2 DM are characterized by 
decreased HDL-C level and hypertriglyceridemia, whereas total 
cholesterol and LDL-C levels are similar to those in nondiabetic 
subjects (Kjeld et al., 2001). The important goal of DM treatment 
is to keep blood glucose, lipid and lipoprotein levels close to 
normal resulting in a reduction of coronary artery disease, a delay 
in onset and a major slowing in the progression of complications 
(Venkateswaran & Pari, 2002). 
Type 2 DM is associated with increased oxidation stress 
(McColl et al., 1997). Free radicals, lipid peroxides and oxidation 
of low-density lipoproteins (LDL) have been suggested to have 
a role in the increased risk of cardiovascular disease (CVD) 
associated with type 2 DM. In diabetes, impaired glucose 
metabolism may lead to an increase in hydroxyl radical 
production. Some complications of DM are associated with 
increased activity of free radical-induced lipid peroxidation and 
accumulation of lipid peroxidation products (Palanduz et al., 
2001). Mechanisms that contribute to increased lipid peroxide 
formation in diabetic patients include : hyperglycemic-induced 
glucose auto-oxidation, non-enzymatic glycation of proteins and 
lipids, increased sorbitol pathway activity, oxidation of advanced 
glycation end-products (AGEs) and cyclooxygenase dependent 
formation of prostaglandin H2 (PGH2) (Kesavulu et al., 2001). 
A variety of natural antioxidants exist to scavenge oxygen free 
radicals and prevent oxidative damage to biological membranes.
Soybean contains complex carbohydrates, protein, dietary fiber, 
oligosaccharides, phytosterol, saponin, lecithin, isoflavone, phytic 
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acid, trypsin inhibitor, and minerals. Complex carbohydrates and 
dietary fiber contents contribute to low glycemic indexes, which 
benefit diabetic individuals (Jenkins et al., 1981) and reduce the 
risk of developing diabetes. Also, soybean reduces cholesterol 
levels (Slameron et al., 1997). When diabetic patients were fed 
diets rich in leguminous seeds, in addition to improved blood 
glucose control, lower serum TG levels were seen than when 
other carbohydrate sources were used, especially for individuals 
with raised serum TG levels (Simpson et al., 1981). It appears 
from several studies that soy-based diets may provide benefits in 
conditions associated with impaired glucose tolerance, hyperlipi-
demia and reduced insulin sensitivity (Hermansen et al., 2001; 
Kang et al., 2006; Lee, 2006). A meta-analysis of 38-controlled 
clinical trials indicated that consumption of 25-50 g soy protein 
was effective in lowering serum T-C (Anderson et al., 1995). 
Polichetti et al. (1996) indicated that the administration of soybean 
lecithin (phosphatidylcholine) to animals with experimentally 
induced hypercholesterolemia decreased the level of plasma T-C, 
LDL-C and increased that of HDL-C when compared to a similar 
supply of polyunsaturated fatty acid. It is reported that 
polyunsaturated soybean phospholipids induce a significant 
reduction in plasma cholesterol levels in hypercholesterolemic 
patients (Kurowska et al., 1997). In prospective randomized 
clinical trials, achieving near-normal glycemic control in patients 
with DM was associated with sustained, decreased rates of 
diabetic complications, including CVD (The diabetes control and 
complications trial research group, 1993). Thus, in the past two 
decades, investigators have focused on the blood glucose, 
lipid-lowering effects of soy-based foods (Tonstard et al., 2002). 
Accordingly, the purpose of this study was to investigate potential 
glucose-lowering and hypolipidemic effects of soybean in type 
2 DM patients. We also examined the effects of soybean on lipid 
peroxidation and antioxidant enzymes activity in type 2 DM 
patients.
Subjects and Methods
Study subjects
This study was approved by the Ethics Committee and the 
Institutional Review Board for Human Subjects Research at 
Hanyang University Hospital, Seoul, Korea and all patients 
signed an informed consent document. Twenty patients with type 
2 DM participated in the study. Patients were selected based on 
the presence of chemistry profiles and OGTT (oral glucose 
tolerance test). All patients had DM with fasting plasma glucose 
levels of 150-300 mg/dl. Patients were randomized into either 
a control group or a soybean group. Exclusion criteria included 
the presence of active liver disease or hepatic and renal 
dysfunction, uncontrolled hypertension, hypo-hyperthyroidism, 
gastrointestinal disease, severe stress, and allergy response to 
soybean. 
Study design
The soybean was washed and dried by hot-air, roasted and 
ground up. Then the soybean powder was made into pills. Pills 
were provided to the soybean supplementation group three times 
a day for 4 weeks. Total daily consumption of soybean equaled 
69 g. Soybean supplement of 69 g provided 23.9 g of protein 
and 18 g of dietary fiber. Diets for DM patients provided 1,800 
kcal and 18 g of dietary fiber daily. Accordingly, the amount 
of dietary fiber intake in the soybean group doubled in 
comparison with the control group. Twenty subjects were divided 
into two groups. Control group was provided a diabetes diet used 
in the hospital. Supplemented group was provided a similar diet 
with the exception of soybean supplementation. The subjects 
continued normal daily activities and exercise patterns.
General characteristics of age, sex, dietary patterns, lifestyle, 
family history, diabetes duration, alcohol intake, smoking and 
treatment type were collected by questionnaire. During the study, 
patients remained on usual medications, diets or lifestyles. 
Nutritional assessments were performed by 24 hour recall method 
at the beginning and end of the experiment. Daily nutrient intake 
was calculated using the Computer Aided Nutritional Analysis 
software (Can-pro, version 3.0, The Korean Nutrition Society) 
based on data from Korean food-composition tables. Other health 
foods or supplement intakes were restricted during the experimental 
period.
Biochemical analysis
Blood samples were obtained at the beginning and end of the 
4-week experiment. We measured blood glucose, lipids (total 
cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol), 
HbA1C after fasting, and 2 hour postprandial blood glucose 
levels. Blood values were analyzed by standard methods at the 
biochemical laboratory of Hanyang University Hospital, a 
certified clinical laboratory.
Laboratory analysis
For erythrocyte lysates, blood was collected in tubes containing 
EDTA and then centrifuged at 1,500 g for 10 minutes at 4℃. 
The supernatant containing the plasma and buffy coat was 
discarded. The red blood cell pellet was washed three times with 
cold saline and frozen immediately at -70℃  until analysis. 
Hemoglobin was separated from the blood cells by precipitation 
with an ethanol/chloroform mixture, followed by continuous 
shaking for 5 min and centrifugation at 2,500 g for 20 min. The 
supernatants were used to determine enzyme activity. 
The total amount of lipid peroxidation products was measured 
with the thiobarbituric acid method, which quantifies plasma 
thiobarbituric acid reactive substances (TBARS) at 532 nm. 
Erythrocyte superoxide dismutase (SOD, EC 1.15.1.1) activity 
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Table 1. The general characteristics of subjects 
Control group Soybean group P-value
Sex (M/F) 4/6 4/6
Age (yr) 54.9 ± 2.4
1) 56.6 ± 2.9 NS
2)
Duration (yr) 4.7 ± 0.9 8.1 ± 2.1 NS
Height (cm) 162.3 ± 2.7 160.8 ± 2.0 NS
Weight (kg) 64.4 ± 1.6 65.0 ± 2.9 NS
BMI (kg/m
2)
3) 24.3 ± 0.6 25.2 ± 1.1 NS
BP (mmHg)
 4)
systolic 126.0 ± 5.2 130.0 ± 3.0 NS
diastolic 79.0 ± 2.7 81.0 ± 1.8 NS
Treatment Type
Hypoglycemic agent (n) 10 8
Hypoglycemic agent + insulin (n) 2
Family History (Yes/No) 2/8 5/5
Drinking (Yes/No) 4/6 2/8
Smoking (Yes/No) 1/9 4/6
1) Mean ± S.E.
2) Not  Significant  at  α=0.05  level  by  independent  t-test
3) BMI  :  Body  Mass  Index
4) B P  :  B l o o d  P r e s s u r e
Table 2. Comparison of nutrients intake in subjects between the two groups
during the supplementation
Control group Soybean group P-value
1)
Carbohydrate (g)  375.4 ± 26.5
2)  351.8 ± 21.6 NS
3)
Fat (g)   47.4 ± 8.3   52.7 ± 3.3 NS
Protein (g)   91.8 ± 9.4   93.2 ± 2.9 NS
Fiber (g)   10.3 ± 0.7   31.1 ± 1.7 p<0.001
Calories (kcal) 2295.4 ± 126.2 2340.6 ± 64.3 NS
CFP ratio
4) 65:19:16 64:20:16
1) Statistical  significance  was  calculated  by  independent  t-test. 
2) Mean ± S.E. 
3) Not  Significant  at  α=0.05  level  by  independent  t-test 
4) CFP  ratio  =  Carbohydrate  :  Fat  :  Protein  ratio
Table 3. Blood glucose levels before and after the supplementation
Control group Soybean group P-value
1)
FBG (mg/dl)
 2)
Baseline 183.0 ± 14.7
3) 169.7 ± 23.0 NS
4 wks 173.0 ± 9.8 109.9 ± 7.7 p<0.001
Changes
4) -12.2 ± 13.5 -57.3 ± 15.5 p<0.05
PP-2hr (mg/dl)
5)
Baseline 278.4 ± 26.1 270.6 ± 33.8 NS
4 wks 258.3 ± 21.5 167.3 ± 21.0 p<0.001
Changes -14.3 ± 17.8 -99.9 ± 15.8 p<0.001
HbA1C (%)
6)
Baseline   8.1 ± 0.3   8.9 ± 0.8 NS
4 wks   7.1 ± 0.2   7.1 ± 0.3 NS
Changes  -1.0 ± 0.4  -1.8 ± 0.5 NS
1) Statistical significance was calculated by an independent t-test between the value 
of  control  and  soybean  groups. 
2) FBG  :  Fasting  Blood  Glucose  level 
3) Mean ± S.E. 
4) Changes  :  The  differences  between  baseline  and  4wks  value
5) PP-2hr  :  Postprandial  Glucose  level 
6) HbA1C  :  Glycosylated  Hemoglobin  A1C  level 
catalase (CAT, EC 1.11.1.6) activity was calculated by 
spectrophotometrically measuring the disappearance of H2O2 at 
240 nm (Aebi, 1984). Erythrocyte glutathione peroxidase 
(GSH-Px, EC 1.4.1.9) activity was assayed according to the 
method of Flohe and Gunzler (1984).
The hemoglobin concentration of lysates was determined 
spectrophotometrically at 546 nm using the cyanomethaemoglobin 
method of Mahoney et al. (1993). All assays were carried out 
in triplicate using a spectrophotometer (Beckman-Coulter DU 
400, Fullerton, CA, USA). 
Statistical analysis
All data were reported as mean ± standard error of the mean. 
The results were statistically analyzed by the SPSS/PC computer 
program (Statistical Package for Social Science 11.0). Differences 
between the control group and the soybean group were assessed 
using an independent t-test. Significance was defined as p<0.05. 
Results
Table 1 shows the general characteristics of the subjects. The 
subjects included 8 males and 12 females. The mean age was 
54.9 ± 2.4 years in the control group and 56.6 ± 2.9 years in the 
soybean group. Pharmacological therapy showed that 18 people 
used oral hypoglycemic agent and 2 people used insulin injection 
and oral hypoglycemic agent. The rate of alcohol intake was 40% 
in the control group and 20% in the soybean group. The rate 
of smoking was 10% in the control group and 40% in the soybean 
group. Height, weight, BMI, and blood pressure of both groups 
at the beginning were not statistically different. The mean BMI 
of subjects showed 24.3 kg/m
2 in the control group and 25.2 
kg/m
2 in the soybean group. The blood pressure of two groups 
was in the normal range (130/80 mmHg or less).
Nutrient intake of subjects is given in Table 2. Intakes of 
macronutrients did not show significant differences between the 
control group and the soybean group with the exception of dietary 
fiber intake (p<0.001), which was higher in patients who were 
fed soybean supplement. Energy composition ratio of C:F:P was 
65:19:16 in the control group, 64:20:16 in the soybean group. 
Mean protein intake of the soybean group was not different from 
that of the control group as determined by 24 hour recall 
including soybean supplement and the mean dietary fiber intake 
in patients who received soybean supplement was 31 g/d.
Table 3 shows the mean change in the blood glucose level 
of the subjects before and after the soybean supplementation. 
The level of fasting blood glucose (FBG), postprandial glucose 
(PP-2hr) and HbA1C of two groups showed no differences at 
the beginning. After soybean supplementation, compared to the 
control group, levels of FBG (p<0.001) and PP-2hr (p<0.001) 
were significantly lower in the soybean group, but the level of 
HbA1C between the control group and the soybean group showed 
no significant differences. The changes of FBG (p<0.05) and 
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Table 4. Blood lipids levels before and after the supplementation
Control group Soybean group P-value
1)
Cholesterol (mg/dl)
Baseline 197.2 ± 16.4
2) 171.2 ± 8.8 NS
3)
4 wks 181.6 ± 10.4 166.6 ± 8.3 NS
Changes
4) -15.6 ± 9.3  -4.7 ± 5.3 NS
Triglyceride (mg/dl)
Baseline 186.6 ± 26.9 167.1 ± 28.6 NS
4 wks 201.3 ± 27.8 145.5 ± 21.0 p<0.05
Changes  15.7 ± 14.1 -21.6 ± 11.2 NS
LDL-Cholesterol (mg/dl)
Baseline 123.8 ± 11.9  97.4 ± 5.1 NS
4 wks 115.6 ± 12.2  98.1 ± 6.6 NS
Changes   -11 ± 6.4   0.7 ± 4.9 NS
HDL-Cholesterol (mg/dl)
Baseline  37.4 ± 2.3  35.3 ± 2.6 NS
4 wks  38.1 ± 2.2  39.0 ± 2.1 NS
Changes   0.7 ± 1.6   3.7 ± 2.0 NS
1) Statistical  significance  was  calculated  by  independent  t-test  between  the  value 
o f  c o n t r o l  a n d  s o y b e a n  g r o u p s . 
2) Mean ± S.E. 
3) Not  Significant  at  α=0.05  level  by  an  independent  t-test 
4) Changes  :  The  differences  between  baseline  and  4wks  value
Table 5. Plasma levels of TBARS and activities of erythrocyte antioxidant 
enzyme of the subjects after soybean supplementation 
Control group Soybean group P-value
1)
TBARS
2)  (μg/mg protein)  27.2 ± 3.6
3) 26.04 ± 7.6 NS
4)
SOD
5)  (unit/mg protein)  0.21 ± 0.02  0.25 ± 0.02 NS
CAT
6)  (unit/mg protein)   0.5 ± 0.08   4.8 ± 0.9 p<0.01
GSH-Px
7)  (unit/mg protein) 0.03 ± 0.07  0.57 ± 0.1 p<0.05
1) Statistical  significance  was  calculated  by  independent  t-test. 
2) TBARS  :  thiobarbituric  acid  reactive  substances 
3) Mean ± S.E. 
4) Not  Significant  at  α=0.05  level  by  an  independent  t-test 
5) SOD  :  superoxide  dismutase  activity 
6) CAT  :  catalase  activity 
7) GSH-Px  :  glutathione  peroxidase  activity 
were significantly larger in comparison with the control group. 
Table 4 shows the mean change in the blood lipids level of 
the subjects before and after 4 weeks of supplementation. The 
level of T-C, TG, LDL-C, HDL-C of two groups showed no 
differences at the beginning. After soybean supplementation, 
compared to the control group, levels of TG (p<0.05) were 
significantly lower in the soybean group. The differences in the 
lipid levels of the subjects before and after the supplementation 
were not significantly different from those of the control group, 
Table 5 shows the antioxidant enzyme activity of the control 
group and the soybean group during the soybean supplementation. 
TBARS levels of the soybean group were not significantly 
different from those of the control group. The levels of CAT 
(p<0.01) and GSH-Px (p<0.05) of the soybean group were 
significantly higher than those of the control group, while the 
level of SOD showed no difference between two groups.
Discussion
In this study, the mean BMI of subjects showed 24.3 kg/m
2 
in the control group and 25.2 kg/m
2 in the soybean group. Unlike 
western countries where obese- type 2 diabetic patients were 70% 
or more, in Korea, obese-type 2 diabetic patients were 35% (Min 
& Huh, 1992).
The Korean Diabetes Association recommended energy 
composition ratio of carbohydrate 55-60%, protein 15-20%, and 
fat 20-25% (Kim et al., 1999). This study showed that 
carbohydrate intake was somewhat higher than the recommended 
CFP ratio. Lee et al. (1994) reported that the mean dietary fiber 
intake of diabetes patients was 17 g/d (10.5 g/1,000 kcal), this 
amount was lower than the DRI (12 g/1,000 kcal). Anderson 
et al. (2004) recommended dietary fiber intake of 25-50 g (15-25 
g/1,000 kcal) for diabetes patients. In this study, the mean dietary 
fiber intake in patients who received soybean supplement was 
31 g/d, which was 2.6 times higher than that in the control group 
and this amount was adequate for DRI.
The level of FBG and PP-2hr in the soybean group after 
supplementation was significantly decreased. The level of 
HbA1C was decreased in both groups but not statistically 
significant. Grace et al. (1986) had reported that soy fiber 
supplementation in the diets of patients with IGT (Impaired 
glucose tolerance) significantly reduced fasting blood glucose 
level and the level of insulin was significantly increased. Also, 
10 g soy polysaccharide had relatively mild effects in reducing 
postprandial plasma glucose level (Alan et al., 1987), soybean 
fiber given to control rats decreased the plasma glucose at 60 
min after the oral glucose test (Zacharia, 1983). The effect of 
improving glucose levels can be explained by the function of 
various components of soybean. The soybean fiber contains 
pectins, galactomannans and arabinogalactans with high viscosity. 
These substances delay gastric emptying and glucose absorption 
(Holf et al., 1979). The effect of soybean fiber may be attributed 
to reduced glucose absorption caused by slowing gastric 
emptying and by limiting the rate of intraluminal diffusion of 
glucose to the absorption surface (Zacharia, 1983). This study 
demonstrated the importance of soybean in the modulation of 
glucose metabolism.
After soybean supplementation, compared to the control group, 
levels of TG (p<0.05) were significantly lower in the soybean 
group. Alan et al. (1987) reported that soy polysaccharide 
significantly reduced the rise of postprandial plasma triglyceride 
levels. The study by Anderson et al. (1980) using high fiber 
diets aimed at improving diabetic control, where 20% of the fiber 
came from legumes, demonstrated lower serum triglyceride 
levels. The study of Zacharia (1983) observed that soybean fiber 
significantly decreased the level of triglycerides in diabetic rats. 
It appears that soybean fiber delayed the absorption of glucose 
and fatty acids from the upper small intestine, thus providing 
less substrate for triglycerides synthesis. In addition, a 
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significant decreases of 9% for T-C, 13% for LDL-C, and 11% 
for TG could be obtained from an average daily intake of around 
47 g of soy protein (Anderson et al., 1995). The FDA recommends 
that 25 g soy protein/day may reduce CVD (Food and Drug 
Administration, 1999). 25 g soy protein/day is similar to the dose 
of our soybean supplement. This suggests that either the soy fiber 
component alone or a synergistic effect between soy fiber with 
the soy protein may be responsible for reducing the level of TG 
in our study. 
Hyperglycemia generates reactive oxygen species which in turn 
cause lipid peroxidation and membrane damage (Hunt et al., 
1988). In our study, soybean supplement didn’t show a decreased 
rate of lipid peroxidation. Concerning to the increases in lipid 
peroxidation, the diabetic patients showed decreased activity of 
the antioxidant SOD, CAT, glutathione, GSH-Px, which play an 
important role in scavenging the toxic intermediate of incomplete 
oxidation. (Kumhhekar & Katyane, 1992). In this study, the 
levels of CAT and GSH-Px of the soybean group were 
significantly higher than those of the control group, while the 
level of SOD was similar in both groups. Soybean supplementation 
increased the activity of enzymes and may help to control free 
radicals. Lee (2006) showed that SOD and GSH-Px activities 
in livers of the STZ-induced diabetic rats were significantly 
decreased compared to the control rats. Also, administration of 
PPEt (Phaseolus vulgaris pod extract) significantly decreased the 
level of TBARS in rats with streptozotocin-induced diabetes and 
increased the activities of SOD, CAT and GSH-Px in diabetic 
rats (Subramanian & Leelavinothan, 2002). SOD is an important 
defense enzyme that catalyses the dismutation of superoxide 
radicals (McCord et al., 1971). CAT is a hemoprotein that 
catalyses the reduction of hydrogen peroxides and protects the 
tissues from highly reactive hydroxyl radicals (Chance et al., 
1952). GSH-Px, an enzyme with selenium catalyzes the reduction 
of hydrogen peroxide and hydroperoxides to non-toxic products. 
These results suggest that soybean supplementation decreases 
oxidative stress due to a combination of improved antioxidant 
activities.
Results from this study suggest that supplementing the diet 
with soybean showed a beneficial effect on the improvement of 
blood glucose control, lipid metabolism and antioxidant enzyme 
activities in type 2 DM patients. Soybean thus may have potential 
use in the management of patients with DM. But, our study was 
limited to a comparison between the control group and the 
soybean group. Hence further randomized, double-blind, placebo- 
controlled studies should be carried out to ensure sufficient 
statistical power and beneficial effect of soybean.
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